Company Performance - Schrodinger, Inc. reported a quarterly loss of 0.74pershare,whichwasbetterthantheZacksConsensusEstimateofalossof0.85, and compared to a loss of 0.21pershareayearago,indicatinganearningssurpriseof12.9447.33 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 17.78%, and this represents an increase from year-ago revenues of 35.19million[2]−Overthelastfourquarters,SchrodingerhassurpassedconsensusEPSestimatestwotimesandtoppedconsensusrevenueestimatestwotimes[2]FutureOutlook−ThesustainabilityofSchrodinger′sstockpricemovementwilldependonmanagement′scommentaryduringtheearningscallandthecompany′searningsoutlook[3][4]−ThecurrentconsensusEPSestimatefortheupcomingquarteris−0.87 on revenues of 42.66million,andforthecurrentfiscalyear,itis−2.83 on revenues of $211.58 million [7] - The estimate revisions trend for Schrodinger is mixed, resulting in a Zacks Rank 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical Info Systems industry, to which Schrodinger belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]